ADC Therapeutics (ADCT) Other financing activities (2023 - 2026)

ADC Therapeutics (ADCT) has reported Other financing activities for 4 consecutive years, with $205000.0 the latest figure, recorded in Q1 2026.

• Quarterly Other financing activities fell 24.35% year-over-year to $205000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.3 million (up 77.11% YoY) and the FY2025 annual result came in at $65.4 million, up 77.04% from the prior year.
• Other financing activities declined to $205000.0 in Q1 2026 per ADCT's latest filing, from $14.6 million in the prior quarter.
• Over the last five years, Other financing activities for ADCT reached as high as $50.5 million in Q2 2025 and fell as low as -$1000.0 in Q4 2023.
• A 4-year average of $11.5 million and a median of $349000.0 in 2023 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2025 — Other financing activities jumped 37.94% — and 2026, when it retreated 24.35%.
• Year by year, Other financing activities stood at -$1000.0 in 2023, then soared by 3660300.0% to $36.6 million in 2024, then slumped by 60.08% to $14.6 million in 2025, then plunged by 98.6% to $205000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $205000.0, $14.6 million, and $50.5 million for Q1 2026, Q4 2025, and Q2 2025 respectively.